QIAGEN N.V. (QGEN) is well-poised to grow in the coming quarter, driven by its strategic alliances with researchers and pharma companies. The company's expansive next-generation sequencing (NSG) portfolio continues to be bolstered by several innovations. Meanwhile, QIAGEN's operations are vulnerable to currency fluctuations, which can adversely affect its financial results. Competitive disadvantages also add to the worry. In the past year, this Zacks Rank #3 (Hold) stock has risen 6% compared with 4% growth ...